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Recently developed CAAX peptidomimetic  com- 
pounds have been shown to be potent and specific in- 
hibitors of farnesyl protein transferase activity and to 
block the growth of Ras-transformed cells. However, 
whether this growth inhibitory action is specifically a 
consequence of blocking oncogenic Ras signaling has 
not been determined. To address this question, we have 
utilized mutants of the normally farnesylated oncogenic 
Ras protein (Ras-F) that are modified by alternative lip- 
ids, a geranylgeranyl isoprenoid (Ras-GG) or the fatty 
acid myristate (Myr-Ras), to determine the specificity of 
the CAAX peptidomimetic compound, B581.  Like  Ras-F, 
both Ras-GG and Myr-Ras are membrane-associated and 
transforming.  Unexpectedly, NIH  3T3 cells transformed 
by each of the three Ras mutants underwent morpho- 
logical alteration to a less transformed,  but  not  normal, 
morphology.  However,  B581 inhibited the ability of only 
Ras-F-transformed cells, but not Ras-GG- or Myr-Ras- 
(or Raf-) transformed cells, to grow in soft agar.  Further- 
more, although all three lipid-modified versions of Ras 
stimulated mitogen-activated protein kinase activation, 
and both Jun and Elk-1 transcriptional activity, B581 
inhibited only farnesylated Ras activation of these three 
downstream components of Ras signaling. Therefore, 
B581 prevents the growth of  Ras-transformed cells by 
specifically antagonizing Ras-mediated signaling. 
Ras  proteins  function  as  critical GDP/GTP-regulated relay 
switches  that control signaling from upstream receptor  tyro- 
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sine  kinases  downstream  to a cascade of serinelthreonine ki- 
nases that include  the mitogen-activated protein  kinases 
(MAP&’; also  known as extracellular  signal-regulated  kinases 
or E R G )  (1, 2). This cascade is  triggered by Ras  interaction 
with the Raf-1 proto-oncogene protein, which in  turn  activates 
the MAPWERK kinases (ME%) (3). ME& are  dual specificity 
kinases that activate MAP&, which translocate  to  the  nucleus 
and  phosphorylate  transcription  factors  to  alter gene  expres- 
sion (4). Oncogenic Ras  triggers  constitutive  activation of this 
cascade of serine/threonine  kinases, which results  in  deregu- 
lated gene  expression and  transformation (5). 
Ras  proteins  mature by undergoing a series of posttransla- 
tional modifications (farnesylation, proteolysis, and  methyla- 
tion)  triggered by a consensus  COOH-terminal CAAX ( C ,  cys- 
teine; A, aliphatic, X ,  S, M, or C )  tetrapeptide sequence (6). The 
attachment of the isoprenoid farnesol  to  the cysteine residue of 
the CAAX motif, which is recognized by the Ras protein: 
farnesyltransferase  (FPTase) enzyme, is  the critical modifica- 
tion  required for Ras  membrane association and  transforming 
activity (6). Nonfarnesylated  mutants of oncogenic Ras  are cy- 
tosolic and completely defective for transformation. However, 
both  Ras  membrane association and  transformation  can be re- 
stored  either by CAAX-signaled geranylgeranylation (7, 8) or 
by addition of an NH,-terminal myristylation  signal sequence 
(9, 10). Thus, while it is clear that  membrane association is 
essential for Ras  transformation,  the precise role of farnesyla- 
tion  remains unclear. 
The  importance of farnesylation  to  Ras  transforming func- 
tion  has prompted the development o f  FPTase  inhibitors  that 
may  serve  as selective agents  to block oncogenic Ras function in 
human  tumors (11). In  particular,  the  generation f compounds 
that  are  based on the  structure of the  Ras CAAX tetrapeptide 
sequence has  resulted  in  several  potent  and specific inhibitors 
of FPTase  activity (11). Although  a second enzyme involved in 
protein  prenylation,  geranylgeranyl protein transferase I, rec- 
ognizes a related CAAX tetrapeptide signal (where X is L), 
these FPTase-directed CAAX-based compounds show strong 
and  preferential  inhibition of FPTase  activity in  vitro and in 
vivo (12-15). 
Present evidence suggests that CAAX peptidomimetics can 
selectively block Ras  transforming activity. For example,  the 
inhibition of colony formation in soft agar of Ras-transformed, 
but  not Mos- or Raf-transformed, cells suggests  that  these com- 
pounds  may be specific inhibitors of oncogenic Ras function in 
vivo (12, 13). However, whether  this  inhibitory action is a direct 
consequence of inhibiting oncogenic Ras  signaling  is  not 
known. 
To address  this  question, we have utilized mutants of onco- 
genic Ras that are modified by alternative lipids.  Since both 
geranylgeranylation  and  myristylation  can  restore  membrane 
association and  transforming activity to  nonfarnesylated  Ras, 
cells transformed by these lipid variants provide ideal controls 
to  evaluate  the specificity and  mechanism of action of CAAX 
peptidomimetics. In this study, we show that  the  B581 CAAX 
peptidomimetic compound (14) selectively blocks farnesylated, 
but  not  geranylgeranylated or myristylated,  Ras  signal  trans- 
duction and transformation. Thus, B581 specifically antago- 
The abbreviations used are: MAPK, mitogen-activated protein ki- 
nase; ERK, extracellular signal-regulated kinase; MEK, MAPWERK 
kinase;  FPTase, Ras protein:farnesyltransferase. 
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FIG. 1. B581 induces   a l te ra t ions   in  the transformed  morphol- 
ogy of cells  expressing  all  three lipid-modified forms of onco- 
genic Ras. Cultures of cells transformed by the  direrent lipid-modified 
Ras(61L)  proteins  were  incubated  in  growth  medium  alone  (panels a+) 
or growth  medium  supplemented  with 250 p~ B581 (panels d-f) or 50 
p~ compactin (panels h and i). Morphologic alteration was observed 
within  48  h.  Panels a, d,  and  h, Ras-F;  panels h and e,  Ras-GG; panels 
c, f ;  and  i, Myr-Ras; panel g, untransformed  NIH  3T3 cells. 
nizes the growth of Ras-transformed cells via blocking onco- 
genic Ras activation of critical downstream events. 
EXPERIMENTAL PROCEDURES 
Ras Constructs and  Ras-transformed Cell Lines-The pZIP-ras-F, 
pZIP-rus-GG, and pZIP-Myr-ras  retrovirus  expression  vector  constructs 
have  been  described  previously  (8,101.  pZIP-ras-F  encodes an oncogenic 
form of human  H-Ras  that  contains  the  activating  Gln-61  to  Leu  mu- 
tation  and  is modified by FPTase  addition of a 15-carbon  farnesyl moi- 
ety. pZIP-rus-GG encodes  a CAAX mutant of Ras(61L) (X is Leu). This 
mutant  protein  is recognized by geranylgeranyl  protein  transferase I 
and  is modified by addition of a  geranylgeranyl  moiety  (8,  16). pZIP- 
Myr-ras encodes a chimeric protein that contains an NH,-terminal 
myristylation signal sequence attached to the nonfarnesylated Ras- 
(61LJ86S) mutant,  in which the Cys  residue of the CAAX sequence has 
been  mutated  to  Ser  (10).  NIH  3T3 cells stably  expressing  each 
Ras(61L)  protein  were  established  after  transfection  and  selection  in 
G418-containing  growth  medium (Dulbecco's modified Eagle's medium, 
10% calf serum)  (8,  10). To compare the effects of inhibiting  farnesyla- 
tion  and  all  isoprenylation, cells were grown in  the absence or presence 
of either 250 p~ B581, an inhibitor of FPTase  (prepared  in  dimethyl 
sulfoxide) (141, or 50 p~ compactin, an inhibitor of the biosynthesis of 
mevalonate  (an  obligate  intermediate  in  the  synthesis of both  farnesyl 
and  geranylgeranyl  isoprenoids)  (6, 11). 
Soft Agar Assay-Colony formation  in soft agar  was performed es- 
sentially as  described  previously  (17). Briefly, single cell suspensions of 
G418-selected NIH  3T3 cells expressing  the  indicated  Ras(61L)  protein 
were  plated  in  agar at a density of 500 cells/well in 12-well plates  in 
growth  medium  containing 0.3% agar.  Parallel  plates  contained  growth 
medium supplemented with 100 p~ B581. Two weeks after plating, 
dishes were stained with 3-[4,5-dimethylthiazol-2-yll-2,5-diphenyltet- 
razolium  bromide;  thiazolyl  blue  (2  mg/ml) for visualization  and  quan- 
titation of colonies. 
MAPK Assay-Activation of the MAPK pathway  in  NIH  3T3 cells 
expressing  the  different  Ras(61L)  proteins  was  determined  essentially 
as  described previously (18). Briefly, cells  were grown in  the  absence or 
presence of B581(250 PM). After 48  h,  total cell extracts  were  prepared 
in Laemmli sample buffer and resolved by sodium dodecyl sulfate- 
polyacrylamide  gel  electrophoresis.  Western  blot  analysis  was  done us- 
Ras(GlL)-transformed cells. Cells  transformed by the indicated on- 
FIG.  2. B581 preferentially blocks the growth of farnesylated 
cogene protein  were  suspended in soft agar  in growth  medium  alone 
(top) or supplemented  with 100 p~ B581  (bottom), as  described  under 
"Experimental Procedures." The degree of inhibition was as  follows: 
Ras-F, 89%; Ras-GG, 54%; Myr-Ras, 50%; and  Raf, 52%. Colonies were 
stained  and  photographed  after  14  days. 
ing 1B3B9, an a n t i - ~ 4 2 ~ ~ ' ~  rabbit antiserum (gift of M. Weber), to 
detect  the  phosphorylated,  active  and  nonphosphorylated,  inactive 
forms of P ~ ~ ~ ~ " ~ / E R K ~ .  
Activation of Jun and Elk-1 Danscriptional Activity--Transient 
transfection  assays  were  used  to  determine  the  activation of Jun  and 
Elk-1  transcriptional  activity as  described  previously (18). The Ga14- 
d u n  (provided by  M. Karin)  and  Gal4-ElkC  (provided by  R. Treisman) 
chimeric expression vectors encode the Gal4 DNA-binding domain 
linked to the transcriptional activation domains of c-Jun  and Elk-1, 
respectively  (19).  The 5X Gal-Luc reporter  plasmid  contains five con- 
sensus  Gal4 DNA-binding sites  upstream of the luciferase gene. "ran- 
sient  transfection  assays  were  done by calcium  phosphate  coprecipita- 
tion  using 2.5 pg of reporter  plasmid, 250 ng of expression vector, and 
250  ng of ras or raf (p22W-raf, encoding an activated form of c-Raf-1) 
plasmids. Following removal of the  transfected DNA, cells were cul- 
tured  in  the absence or presence of 250 p~ B581 for 30 h. Luciferase 
activity  was  assayed  and  quantitated  as  described  previously (18). 
RESULTS AND DISCUSSION 
B581 Preferentially Blocks Growth of Farnesylated Ras- 
(6lL)"we  have previously shown that B581, an  inhibitor of 
the Ras FPTase, preferentially blocks farnesylation versus 
geranylgeranylation in  vitro and in vivo (14). To extend these 
observations to Ras  activity in  mammalian cells, we first de- 
termined  the  ability of B581 to reverse the  transformed prop- 
erties of Ras-transformed cells. 
NIH  3T3 cells expressing the different lipid-modified 
Ras(61L) proteins were grown in  the absence or presence of 
B581. Like authentic farnesylated Ras-F, both Ras-GG and 
Myr-Ras also cause morphologic transformation (Fig. 1, panels 
a-c) .  Surprisingly, we observed that B581 treatment caused  a 
similar  alteration  in  the morphology of all three  transformed 
cell populations (Fig. 1, panels  d-f). Although the cells exhib- 
ited a less refractile and more adherent  appearance,  this cel- 
lular morphology was quite distinct from the morphology of 
untransformed NIH 3T3 cells (Fig. 1, panel g). Instead, the 
cells showed a relatively flattened  and  rather cuboidal mor- 
phology and  appeared  as  tight  clusters of cells with less distinct 
cell-cell junctions. This B581-induced morphologic change  was 
distinct from the extremely  rounded and  less  adherent pheno- 
type seen  with compactin-treated cells (Fig. l ,  panels h and i ) .  
Compactin-induced growth  inhibition and morphological 
changes  have previously been shown not to be a consequence of 
blocking Ras function (20). Because both Ras-GG- and Myr- 
Ras-transformed cells also showed the  same  alteration  in  re- 
sponse to B581 treatment as did Ras-F-transformed cells, it  
suggested that B581  caused a nonspecific effect that  was inde- 
pendent of Ras function. We therefore evaluated the conse- 
quences of B581 on the growth  properties of these cells. 
As shown in Fig. 2, B581 preferentially blocked the ability of 
NIH  3T3 cells expressing  Ras-F versus cells expressing Ras-GG 
or Myr-Ras to proliferate in soft agar. As expected, B581 also 
had limited effect on the soft agar colony formation of cells 
CAAX Peptidomimetic Inhibition of Ras Function 
Ras-F Ras-GG Myr-Ras 
0 - 
1 2 3 1 2 3 1 2 3  
FIG. 3. MAPK activation is selectively  blocked by B581 only in 
cells transformed  by  farnesylated Ras-F. Cells transformed by the 
indicated Ras(61L) protein  were  incubated in growth  medium supple- 
mented with the following: lanes I, dimethyl  sulfoxide (1%) vehicle only; 
lanes 2, 250 PM B581; lanes 3, 50 PM compactin. Immunoblotting of 
~ 4 2 ~ ~  shows the inactive, unphosphorylated (bottom bands) and  ac- 
tive, phosphorylated  forms (upper bands). The  reduced levels of ~ 4 2 ~ ‘ ~  
in the lanes with compactin-treated cells was a consequence of the 
Ras-independent  growth inhibition due to compactin. 
expressing constitutively activated human Raf,  which lies 
downstream of Ras and can cause transformation in a Ras- 
independent fashion. Therefore, the activity of the FPTase in- 
hibitor B581 in preventing anchorage-independent cellular 
proliferation of Ras-transformed cells can be ascribed to its 
ability to specifically interfere  with farnesylation of oncogenic 
RaS. 
B581 Specifically Blocks Farnesylated Ras(61L) Activation of 
MAPKs-Since MAP% are constitutively activated in Ras- 
transformed NIH  3T3  cells (1-31, their activation provides an 
excellent marker for the activation of the Ras signal  transduc- 
tion pathway. We therefore determined whether ~ 4 2 ~ ~  was 
constitutively activated in NIH 3T3 cells transformed by the 
different lipid-modified forms of Ras(61L), and if so, whether 
B581 could selectively block its activation in cells transformed 
by Ras-F. 
MAP& are activated by  MEK phosphorylation of tyrosine 
and threonine residues, and the phosphorylated, activated 
forms show a slower electrophoretic mobility (3). We observed 
that NIH 3T3 cells transformed by any one of the  three lipids 
can cause constitutive activation of MAPKs (Fig. 3, lanes 1 ). 
Thus, the transforming function of these  alternatively modified 
Ras proteins is apparently mediated by the  same downstream 
signaling  events as authentic Ras(61L). 
Treatment of parallel  cultures showed that B581 specifically 
prevented the ability of Ras-F, but not Ras-GG or Myr-Ras, to 
activate ~ 4 2 ~ ~  (Fig. 3, lanes 2). In contrast, compactin 
blocked the activity of Ras modified by either a farnesyl or a 
geranylgeranyl isoprenoid but  had no  effect on Ras modified by 
the  fatty acid myristate (Fig. 3, lanes 3). These results demon- 
strate  that pharmacological inhibition of Ras farnesylation pre- 
vents  the ability of Ras to  transduce  signals to activate down- 
stream cellular targets such as MAPKs. 
B581 Selectively  Blocks Farnesylated Ras(61L) Stimulation 
of c-Jun  and Elk-1 Danscriptional Activity-We next evalu- 
ated two downstream events triggered by oncogenic Ras. Elk-1 
transcriptional activity is stimulated by MAPK phosphoryla- 
tion, while the MAPK-related Jun kinase phosphorylates and 
stimulates Jun transcriptional activity (18, 19,21). Since both 
MAPK and MAPK-related Jun kinase activities are triggered 
by oncogenic Ras (and Raf), we determined the ability of B581 
to block Elk-1 and  Jun stimulation by the different Ras mu- 
tants. We observed that B581 selectively inhibited Ras-F but 
not Ras-GG,  Myr-Ras, or Raf-induced activation of Jun (Fig. 
4A) and Elk-1 (Fig. 4B). These results indicate that B581 
showed selective inhibition of signaling induced only by Ras-F. 
An essential  requirement for a useful CAAX peptidomimetic 
must be its ability to preferentially antagonize FPTase modifi- 
cation of Ras. Since the majority of prenylated proteins in 
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FIG. 4. B581 selectively blocks  Jun  and Elk-1 transcriptional 
activation  induced  only by oncogenic  farnesylated Ras-F. “ran- 
(panel A )  or Gal4-ElkC (panel B )  in the absence or presence of 250 ~.IM 
sient transfection luciferase assays were done with either Gal4-Jun 
B581 as described  under  “Experimental  Procedures.” T w o  experiments 
were  performed in triplicate. Values  are  normalized to the activity (in 
relative luciferase units) of  vector alone. DMSO, dimethyl sulfoxide. 
l l ) ,  a lack of specificity of a CAAX peptidomimetic may result 
in significant undesirable consequences. We show here  that  the 
B581 CAAX peptidomimetic compound selectively antagonizes 
the ability of farnesylated, but not geranylgeranylated, Ras 
function and  that  the inhibitory action of this compound is a 
consequence of specifically  blocking the downstream action of 
oncogenic Ras. 
The observation that B581 induced morphological alter- 
ations in a farnesylated Ras-independent fashion suggests that 
the function of other farnesylated proteins may also be per- 
turbed by  B581. The farnesylated Ras-related protein, RhoB, 
which is a regulator of actin cytoskeletal organization (221, is a 
possible target for B581 action. B581 also blocks the farnesy- 
lation of nuclear  lamins (14) and may also alter  their function 
(6). However, the continued growth of both Raf- and Myr-Ras- 
transformed cells in soft agar suggests that neither of these 
effects is the basis of the ability of B581 to  inhibit he growth of 
the Ras-F-transformed cells. These results suggest that impair- 
ment of the function of other farnesylated proteins may not be 
deleterious to cell viability and provide further evidence that 
CAAX-based FPTase inhibitors may be useful agents for cancer 
treatment. 
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